in the US, there were around 400 branded drugs, that have no competition, are off patent and can have ANDA’s submitted against them. But don’t. A lot of these drugs only have yearly sales of $30 million or less, or are a complex drug compounds to replicate. And it seems the large Pharma Coys are not interested in these therapy’s, even though they are very profitable. That may be the space ACR is positioning itself for. Jet ( information sourced from FDA site)
Add to My Watchlist
What is My Watchlist?
